Breaking Ground on Gender Dysphoria in Minors: Joint Effort by Ministry of Health and Family to Develop Evidence-Based Guidelines and Best Practices for Triptorelin Use

Schillaci and Roccella Collaborating on New guidelines for Triptorelin Dysphoria

In a joint effort, the Ministry of Health and the Ministry of Family have launched a discussion on gender dysphoria in minors, with a particular focus on the use of triptorelin, a puberty blocking drug. This initiative is being led by Ministers Orazio Schillaci and Eugenia Roccella, who are determined to develop evidence-based guidelines and best practices for this complex issue.

The two ministries have announced their collaboration through a joint statement that summarizes the work done so far on gender dysphoria and the use of blockers. The statement highlights that this initiative follows a hearing with scientific societies involved in the issue of gender dysphoria in adolescents and a request made to the National Bioethics Committee to reevaluate the use of triptorelin in cases of dysphoria in minors. In addition, the ministries are conducting a survey among regions regarding clinical monitoring, expenditures, and prescriptions of triptorelin for cases of dysphoria, and have requested a report from AIFA on the therapeutic indications for the drug.

This collaborative effort represents an important step towards addressing gender dysphoria in minors proactively. As experts continue their work to develop new guidelines based on scientific literature and experiences from other countries reevaluating their positions after widespread use of these drugs, we can expect updates on this important issue in the coming days. Stay tuned for more information as this table of technicians and experts continues its work to provide evidence-based guidance on this complex topic.

Leave a Reply